Journal of Clinical Oncology

Reply to: Mifamurtide in Nonmetastatic High-Grade Osteosarcoma

E Emanuela Palmerini (Osteoncologia, Sarcomi dell'Osso e dei Tessuti Molli, e Terapie Innovative - IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy) M Massimo Serra (Emanuela Palmerini, MD, PhD, Osteoncology, Bone and Soft Tissue Sarcomas, and Innovative Therapies Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL; Massimo Serra, PhD, and Toni Ibrahim, MD, PhD, Osteoncology, Bone and Soft Tissue Sarcomas, and Innovative Therapies Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy; and Javier Martín Broto, MD, PhD, Research Health Institute of Fundacion Jimenez Diaz (IIS/FJD; UAM), Madrid, Spain, Department of Medical Oncology, Fundacion Jimenez Diaz University Hospital, Madrid, Spain, University Hospital General de Villalba, Madrid, Spain) T Toni Ibrahim J Javier Martin Broto (Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain)
View Original
APA MLA Chicago BibTeX RIS

Article Details

Volume / Issue Vol. 44, Issue 11
Published April 10, 2026
Pages 1060-1061
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins
ISSN: 0732-183X Health Sciences

Authors (4)

E

Emanuela Palmerini

Osteoncologia, Sarcomi dell'Osso e dei Tessuti Molli, e Terapie Innovative - IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy

M

Massimo Serra

Emanuela Palmerini, MD, PhD, Osteoncology, Bone and Soft Tissue Sarcomas, and Innovative Therapies Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL; Massimo Serra, PhD, and Toni Ibrahim, MD, PhD, Osteoncology, Bone and Soft Tissue Sarcomas, and Innovative Therapies Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy; and Javier Martín Broto, MD, PhD, Research Health Institute of Fundacion Jimenez Diaz (IIS/FJD; UAM), Madrid, Spain, Department of Medical Oncology, Fundacion Jimenez Diaz University Hospital, Madrid, Spain, University Hospital General de Villalba, Madrid, Spain

T

Toni Ibrahim

J

Javier Martin Broto

Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain

Related Articles from this Journal

Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer

Ismaela Anna Vascotto, Filippo Antonica et al. Aug 2026 10.1200/jco-26-00658

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial

Samer A. Srour, Jad Chahoud et al. Aug 2026 10.1200/jco-26-00388

Adjuvant Carboplatin for Early-Stage, Triple-Negative Breast Cancer: Taxane and Patient Selection

Risako Komata, Kenju Ando et al. Aug 2026 10.1200/jco-26-00140

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)

Ghayas C. Issa, Branko Cuglievan et al. Aug 2026 10.1200/jco-26-01743

Reply to: Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer

Irbaz Bin Riaz, R. Bryan Rumble et al. Aug 2026 10.1200/jco-26-01001